Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Payables (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Payables for 11 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Payables fell 25.92% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 25.92% year-over-year, with the annual reading at $1.3 million for FY2025, 25.92% down from the prior year.
  • Payables for Q4 2025 was $1.3 million at Marker Therapeutics, down from $1.7 million in the prior quarter.
  • The five-year high for Payables was $11.1 million in Q4 2021, with the low at $1.3 million in Q4 2025.
  • Average Payables over 5 years is $3.5 million, with a median of $2.4 million recorded in 2022.
  • Peak annual rise in Payables hit 131.89% in 2022, while the deepest fall reached 77.36% in 2022.
  • Over 5 years, Payables stood at $11.1 million in 2021, then tumbled by 77.36% to $2.5 million in 2022, then plummeted by 30.78% to $1.7 million in 2023, then increased by 0.5% to $1.8 million in 2024, then dropped by 25.92% to $1.3 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $1.3 million, $1.7 million, and $2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.